Physician profile
Amber Survant
NPI 1407371289
$3,634.80
in general payments reported to CMS, 2019-2025
17 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $421 · 2023: $858 · 2024: $840 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,925 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,925.25 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,159.27 | 2022-2025 | Caplyta |
| Abbvie INC. | $529.44 | 2021-2025 | |
| Noven Therapeutics, LLC | $339.36 | 2023-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $255.37 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $240.27 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $224.50 | 2021-2025 | Ingrezza |
| Corium, LLC | $179.65 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $162.55 | 2021-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $124.64 | 2021-2025 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $100.90 | 2021-2023 | Trintellix |
| Axsome Therapeutics, INC. | $89.82 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $81.54 | 2024-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $66.75 | 2023-2024 | Dyanavel Xr |
| Neuronetics, INC. | $37.28 | 2022-2024 | Neurostar Tms Therapy System |
| Collegium Pharmaceutical, INC. | $18.16 | 2025 | Jornay Pm |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.84 | 2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Survant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.